Article
Myovant rejects Sumitovant and Sumitomo's $2.5bn acquisition offer
Rating:
0.0
Views:
53
Likes:
1
Library:
1
Myovant Sciences has rejected a $2.5bn acquisition from Sumitovant Biopharma Sumitomo Pharma, citing that it 'undervalues' the company.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value